SOM Biotech 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 


«12345678910111213...1718»
  • ||||||||||  Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
    Clinical, Preclinical, Journal:  In vitro activities of eravacycline against clinical bacterial isolates: a multicenter study in Guangdong, China. (Pubmed Central) -  Dec 3, 2024   
    Eravacycline (ERV), a novel tetracycline derivative, exhibits broad-spectrum antibacterial activity, but data on the bacterial activity against Chinese bacterial isolates are very scarce...Since there were no intermediate breakpoints for the eravacycline, the MIC values measured by the ETEST method might result in lower CA and higher VME and ME. This study provides MIC values of eravacycline against Gram-positive and Gram-negative pathogens in four hospitals in Guangdong Province, and eravacycline is an effective therapeutic candidate for common bacteria.
  • ||||||||||  Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
    Journal:  Eradication of Pseudomonas aeruginosa Persister Cells by Eravacycline. (Pubmed Central) -  Nov 16, 2024   
    The effects of eravacycline on persister control were further validated in vivo using a lung infection model in mice. Collectively, these results demonstrate the possibility to control persister cells of bacterial pathogens by targeting dormancy.
  • ||||||||||  Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
    Journal, PD(L)-1 Biomarker, IO biomarker:  Eravacycline improves the efficacy of anti-PD1 immunotherapy via AP1/CCL5 mediated M1 macrophage polarization in melanoma. (Pubmed Central) -  Nov 13, 2024   
    As expected, application of ERV improved the efficacy of anti-PD1. Overall, our results approved that ERV enhances the efficacy of anti-PD1 immunotherapy in melanoma by promoting the polarization of M1 macrophages, which provided novel therapeutic strategy for improving the effectiveness of melanoma anti-PD1 immunotherapy.
  • ||||||||||  prexasertib (ACR-368) / Acrivon Therap
    Aberrant Splicing in CHEK1 Is a Driver of Megakaryocytic Dysplasia in U2AF1S34F Mutant Myelodysplastic Syndromes (Halls G-H (San Diego Convention Center)) -  Nov 6, 2024 - Abstract #ASH2024ASH_5696;    
    CHK1 inhibitor Prexasertib treatment resulted in a significant increase in the ploidy level of HEL and K562 cells with overexpressed U2AF1S34F...In U2AF1S34 mutant MDS, CHEK1 isoform switching resulted aberrant phosphorylated CHK1 may arrest the cell cycle, with impairing the MK polyploidization and blocking the maturation. Therefore, CHK1 inhibitor can promote U2AF1S34F mutant megakaryocyte maturation and may serve as a novel therapy in MDS.
  • ||||||||||  MIK665 / Novartis, HitGen, prexasertib (ACR-368) / Acrivon Therap, crenolanib (ARO-002) / AROG
    High-Throughput Drug Repurposing Identifies SN-38 As a Potent Inhibitor of AML with Synergistic Effects in Combination with PARP and BCL-2 Inhibitors for Treating KMT2A-Rearranged Leukemias (Halls G-H (San Diego Convention Center)) -  Nov 6, 2024 - Abstract #ASH2024ASH_3865;    
    Results : High Throughput Drug Screening identified the top five most active FDA-approved drugs across 6 AML cell lines : 1) SN-38 (a topoisomerase I inhibitor and the active metabolite of irinotecan), 2) Triplotide (an NF-?B inhibitor), 3) Mitoxantrone (a topoisomerase II inhibitor), 4) Idarubicin (a topoisomerase II inhibitor), and 5) Bortezomib (a proteasome inhibitor)...Drugs that exhibited greater selectivity, meaning greater responses in KMT2Ar cell lines, included : 1) Ingenol Mebutate (a PKC inhibitor), 2) a BET bromodomain inhibitor, 3) MIK665 (an MCL1 inhibitor), 4) Prexasertib (a CHK inhibitor), and 5) Crenolanib (an FLT3/PDGFR inhibitor)...Moreover, the observed synergy with PARP and BCL-2 inhibitors reveals strategies to overcome AML resistance mechanisms to SN-38. However, rigorous preclinical and clinical studies are essential to validate its efficacy, safety, and optimal dosing regimens.
  • ||||||||||  gepotidacin (GSK2140944) / GSK, epetraborole (AN3365) / AN2 Therap, Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
    Screening of the Pandemic Response Box library identified promising compound candidates against extensively drug-resistant Acinetobacter baumannii (Convention Center - Hall I-1 (1st Floor); In-Person-Only) -  Oct 11, 2024 - Abstract #ASTMH2024ASTMH_1528;    
    Our findings highlight gepotidacin, epetraborole, and eravacycline as promising candidates for further evaluation in murine wound infection models against multidrug-resistant A. baumannii. These compounds hold potential for addressing the critical need for effective antibiotics in the face of rising antimicrobial resistance.
  • ||||||||||  bevantolol (SOM3355) / SOM Biotech
    Trial completion:  Efficacy and Safety on SOM3355 in Huntington's Disease Chorea (clinicaltrials.gov) -  Sep 23, 2024   
    P2,  N=140, Completed, 
    Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025 Active, not recruiting --> Completed
  • ||||||||||  Mycamine (micafungin) / Astellas, Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
    Mycobacterium abscessus Peritonitis: An Uncommon Yet Significant Cause of Peritoneal Dialysis-Associated Peritonitis (Exhibit Hall, Convention Center) -  Sep 23, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_2750;    
    If Mycobacterium species are detected, further analysis using genome-wide sequencing is recommended to confirm the specific strain of Mycobacterium involved. Prompt removal of the catheter along with peritoneal washout is crucial for achieving clinical improvement and preventing further complications.
  • ||||||||||  Nuzyra (omadacycline) / Paratek, Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
    Journal:  Emergence of plasmid-borne tet(X4) resistance gene in clinical isolate of eravacycline- and omadacycline-resistant Klebsiella pneumoniae ST485. (Pubmed Central) -  Sep 3, 2024   
    Importantly, our study raises concerns that plasmid-mediated resistance to omadacycline and eravacycline may spread further to a variety of ecological and clinical pathogens, limiting the choice of medication for extensively drug-resistant bacterial infections. Therefore, it is important to continue to monitor the prevalence and spread of tet(X4) and other tetracyclines resistance genes in K. pneumoniae and diverse bacterial populations.
  • ||||||||||  tetracycline / Generic mfg.
    Journal, Adverse events:  Safety profiles of Tetracycline-class drugs: a pharmacovigilance analysis of the FAERS database. (Pubmed Central) -  Aug 19, 2024   
    Three new antibiotics, tigecycline, omadacycline, and eravacycline, approved within the past 18?years, and represent a new era in the use of tetracyclines...Patients aged 12-18 and treatment with minocycline are risk factors for thyroid adverse events(12-18: OR?=?10.727 [7.113-16.177], p?<?0.0001; minocycline: OR?=?17.025 [10.475-27.678], p?<?0.0001).Second-generation tetracycline and third-generation tetracycline ADR patterns differed...This study investigated adverse events highly associated with tetracyclines treatment, which provided basic evidence for further research on tetracyclines-related adverse events for children. However, the safety of third-generation tetracycline in children requires additional validation through a large-scale prospective study.
  • ||||||||||  tetracycline / Generic mfg.
    Journal:  Enhancing outer membrane permeability of tetracycline antibiotics in P. aeruginosa using TOB-CIP conjugates. (Pubmed Central) -  Aug 12, 2024   
    The structure-activity relationship investigation indicates that the flexible hydrophobic C12 carbon-chain linker in TOB-CIP conjugate 1a is an optimal potentiator of tetracyclines against tetracycline-resistant and -susceptible strains of P. aeruginosa. Furthermore, conjugate 1a consistently synergized with the 3rd generation tetracycline, eravacycline, in P. aeruginosa PAO1 in the presence of up to 25% fetal bovine serum (FBS).
  • ||||||||||  Invanz (ertapenem) / Merck (MSD), Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
    A RARE CASE OF LEUCONOSTOC GROWTH IN PLEURAL FLUID AND LACTOBACILLUS FROM A MEDIASTINAL ABSCESS (Convention Center Exhibit Hall: Poster Area 2) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_5328;    
    This is the first case report to our knowledge to document Leuconostoc species growth from pleural fluid culture. Although these bacterial species are unfamiliar infections of pleural fluid and abscess, it is crucial to know how to navigate treatment, especially at hospitals in which susceptibility testing is not routinely performed.
  • ||||||||||  tetracycline / Generic mfg.
    Review, Journal:  Third-Generation Tetracyclines: Current Knowledge and Therapeutic Potential. (Pubmed Central) -  Jul 31, 2024   
    Additionally, we will explore their therapeutic potential, analyzing their primary indications of prescription, potential future uses, and non-antibiotic features. This review aims to provide valuable insights into the clinical applications of third-generation tetracyclines, thereby enhancing understanding and guiding optimal clinical use.
  • ||||||||||  epetraborole (AN3365) / AN2 Therap, Luzu (luliconazole) / Bausch Health, Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
    Preclinical, Journal:  Evaluation of MMV Pandemic Response Box compounds to identify potent compounds against clinically relevant bacterial and fungal clinical isolates in vitro. (Pubmed Central) -  Jul 23, 2024   
    MMV1580854, MMV1579788, eravacycline and epetraborole inhibited both the bacterial test isolates...Five compounds from MMV Pandemic Box were found to be inhibiting colistin and ceftazidime resistant A. baumannii clinical isolate, also against colistin and ?-lactam resistant P. aeruginosa clinical isolate...MMV1782110, Eberconazole, amorolfine and luliconazole exhibited potent anti-fungal activity. Further investigations are warranted to identify the targets and mechanism.
  • ||||||||||  Review, Journal:  Unveiling the Secrets of Acinetobacter baumannii: Resistance, Current Treatments, and Future Innovations. (Pubmed Central) -  Jul 13, 2024   
    Furthermore, the potential of phage therapy, as well as deep learning and artificial intelligence, offer a complementary approach that could be particularly useful in cases where traditional strategies fail. The fight against A. baumannii is not confined to the microcosm of microbiological research or hospital wards; instead, it is a broader public health dilemma that demands a coordinated, global response.
  • ||||||||||  Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
    Preclinical, Review, Journal, Real-world evidence, Real-world:  Eravacycline: a comprehensive review of in vitro activity, clinical efficacy, and real-world applications. (Pubmed Central) -  Jun 16, 2024   
    Despite common gastrointestinal adverse events, eravacycline maintains an overall favorable safety profile, reinforcing its status as a tolerable antibiotic. However, ongoing research is essential for refining eravacycline's role, exploring combination therapy, and assessing its performance against biofilms, contributing to its continued success in combating challenging bacterial infections.
  • ||||||||||  prexasertib (ACR-368) / Acrivon Therap
    Journal:  Mis-splicing of mitotic regulators sensitizes SF3B1-mutated human HSCs to CHK1 inhibition. (Pubmed Central) -  Jun 10, 2024   
    Clinical CHK1i prexasertib selectively targeted SF3B1-mutant HSCs and abrogated engraftment in vivo. These findings identify mis-splicing of mitotic regulators in SF3B1-mutant HSCs as a targetable vulnerability engaged by pharmacological CHK1 inhibition.
  • ||||||||||  Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
    New P4 trial:  TheraCRAB: Therapeutic Options for CRAB (clinicaltrials.gov) -  Jun 2, 2024   
    P4,  N=108, Not yet recruiting, 
  • ||||||||||  Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva, Zemdri (plazomicin) / Ionis, Achaogen
    Review, Journal:  Multi-resistant organisms in burn patients: an end or a new beginning. (Pubmed Central) -  May 23, 2024   
    Accurate and rapid diagnostic and monitoring tools for detecting MDROs in burn patients should be developed. The emergence of MDROs in burn care is a challenge and a new beginning in infection innovation and novel treatments.
  • ||||||||||  Retrospective data, Journal, Gram negative:  Assessing Clinician Utilization of Next-Generation Antibiotics Against Resistant Gram-Negative Infections in U.S. Hospitals : A Retrospective Cohort Study. (Pubmed Central) -  May 20, 2024   
    To determine use patterns of recently U.S. Food and Drug Administration (FDA)-approved gram-negative antibiotics (ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, plazomicin, eravacycline, imipenem-relebactam-cilastatin, and cefiderocol) and identify factors associated with their preferential use (over traditional generic agents) in patients with gram-negative infections due to pathogens displaying difficult-to-treat resistance (DTR; that is, resistance to all first-line antibiotics)...Patients were treated exclusively using traditional agents in 1091 of 2631 DTR episodes (41.5%), including "reserve" antibiotics such as polymyxins, aminoglycosides, and tigecycline in 865 of 1091 episodes (79.3%)...U.S. Food and Drug Administration; NIH Intramural Research Program.